Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunomedics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Immunomedics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Immunomedics Enters into Research Agreement with Yale Cancer Center 12
Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 13
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 14
Immunomedics Expands Clinical Collaboration with AstraZeneca 15
Clovis Oncology Enters into Agreement with Immunomedics 16
Immunomedics Enters into Agreement with University of Wisconsin Carbone Cancer Center 17
Immunomedics Enters Into Co-Devlopment Agreement With Algeta For Epratuzumab 18
Equity Offering 19
Immunomedics Raises USD276 Million in Public Offering of Shares 19
Immunomedics to Raise USD75 Million in Private Placement of Shares 21
Immunomedics Plans to Raise Funds through Public Offering of Shares 23
Immunomedics Raises USD125 Million in Private Placement of Series A-1 Preferred Stock 24
Immunomedics Raises USD30 Million in Public Offering of Shares and Warrants 25
Immunomedics Completes Public Offering Of Shares For US$30.2 Million 27
Immunomedics Completes Public Offering Of Common Stock For US$16 Million 29
Debt Offering 30
Immunomedics Raises USD85 Million in Private Placement of 4.75% Notes Due 2020 30
Asset Transactions 32
Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 32
Acquisition 33
Seattle Genetics Acquires 2.8% Stake in Immunomedics 33
Immunomedics Inc – Key Competitors 35
Immunomedics Inc – Key Employees 36
Immunomedics Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Nov 07, 2018: Immunomedics announces first quarter fiscal 2019 results and provides corporate update 38
Aug 23, 2018: Immunomedics announces fourth quarter and fiscal year 2018 results and provides corporate update 40
May 09, 2018: Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update 42
Feb 08, 2018: Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update 44
Nov 09, 2017: Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update 46
Aug 16, 2017: Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline 48
May 10, 2017: Immunomedics Announces Third Quarter Fiscal 2017 Results And Clinical Program Developments 50
Feb 09, 2017: Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments 52
Corporate Communications 54
Apr 09, 2018: Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer 54
Jan 09, 2017: Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan 55
Legal and Regulatory 56
Feb 21, 2017: Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws 56
Government and Public Interest 57
May 05, 2017: Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value 57
Product News 60
11/09/2017: Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth 60
02/23/2017: Immunomedics Announces Company’s Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies 62
02/17/2017: Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer 63
01/26/2017: venBio Releases Presentation Detailing Urgent Case for Change at Immunomedics 64
01/18/2017: Immunomedics Announces New Data for IMMU-132 at Investor R&D Day 65
Product Approvals 68
Aug 16, 2017: Immunomedics provides update on IMMU-132 68
Clinical Trials 69
Dec 06, 2017: Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) 69
Nov 13, 2017: Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium 70
Sep 11, 2017: Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer 71
Aug 21, 2017: Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer 72
Jul 10, 2017: Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics’ Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers 73
Apr 05, 2017: Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients with Metastatic Small-Cell Lung Cancer who are Sensitive or Resistant to First-Line Chemotherapy 75
Apr 04, 2017: Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan 76
Apr 04, 2017: Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression 77
Mar 15, 2017: Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer 78
Jan 09, 2017: Immunomedics Announces Antitumor Effect of Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer Can be Enhanced With DNA-Repair Inhibitors 80
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82
Immunomedics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunomedics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunomedics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Immunomedics Enters into Research Agreement with Yale Cancer Center 12
Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 13
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 14
Immunomedics Expands Clinical Collaboration with AstraZeneca 15
Clovis Oncology Enters into Agreement with Immunomedics 16
Immunomedics Enters into Agreement with University of Wisconsin Carbone Cancer Center 17
Immunomedics Enters Into Co-Devlopment Agreement With Algeta For Epratuzumab 18
Immunomedics Raises USD276 Million in Public Offering of Shares 19
Immunomedics to Raise USD75 Million in Private Placement of Shares 21
Immunomedics Plans to Raise Funds through Public Offering of Shares 23
Immunomedics Raises USD125 Million in Private Placement of Series A-1 Preferred Stock 24
Immunomedics Raises USD30 Million in Public Offering of Shares and Warrants 25
Immunomedics Completes Public Offering Of Shares For US$30.2 Million 27
Immunomedics Completes Public Offering Of Common Stock For US$16 Million 29
Immunomedics Raises USD85 Million in Private Placement of 4.75% Notes Due 2020 30
Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 32
Seattle Genetics Acquires 2.8% Stake in Immunomedics 33
Immunomedics Inc, Key Competitors 35
Immunomedics Inc, Key Employees 36
Immunomedics Inc, Subsidiaries 37
List of Figures
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10